Product Information
HUMIRA(CF) PEN 40 MG/0.4 ML is a brand product labeled by AbbVie Inc., priced at $3367.4148 per EA under NDC 00074055402. Its NADAC has been published 407 times since Dec 19, 2018.
Manufacturer
AbbVie Inc.NDC
00074055402
Classification
Brand
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Biologic (BLA)
FDA Application
BLA125057On Market Since
3/9/2016
Price Statistics
The NADAC for HUMIRA(CF) PEN 40 MG/0.4 ML has been published 407 times since Dec 19, 2018, and over the history we have for it it has risen 42.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3367.4148 per EA |
|---|---|
| All-time high | $3371.4911 (Feb 14, 2024) |
| All-time low | $2371.9480 (Dec 19, 2018) |
| 52-week high | $3367.4148 |
| 52-week low | $3363.6935 |
| Median price | $3121.7510 |
| Average price | $3074.1239 |
| Largest weekly change | +8.0% (Jan 11, 2023) |
| Weeks tracked | 407 |
| Tracking since | Dec 19, 2018 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AbbVie Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Adalimumab market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of HUMIRA(CF) PEN 40 MG/0.4 ML?
The current National Average Drug Acquisition Cost (NADAC) for HUMIRA(CF) PEN 40 MG/0.4 ML, manufactured by AbbVie Inc., is $3367.4148 per EA (NDC 00074055402), effective Sep 30, 2026.
How has the price of HUMIRA(CF) PEN 40 MG/0.4 ML changed over time?
Over the history we have for it, the NADAC for HUMIRA(CF) PEN 40 MG/0.4 ML has risen 42.0%. It has been tracked across 407 weekly CMS publications since Dec 19, 2018.
What are the highest and lowest recorded NADAC prices for HUMIRA(CF) PEN 40 MG/0.4 ML?
Since Dec 19, 2018, the NADAC for HUMIRA(CF) PEN 40 MG/0.4 ML has ranged from a low of $2371.9480 (Dec 19, 2018) to a high of $3371.4911 (Feb 14, 2024), with a median of $3121.7510 per EA.
Are there cheaper alternatives to HUMIRA(CF) PEN 40 MG/0.4 ML?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, HUMIRA(CF) 20 MG/0.2 ML SYRINGE, is $3366.1230 per EA — about 0% below HUMIRA(CF) PEN 40 MG/0.4 ML.
Who manufactures HUMIRA(CF) PEN 40 MG/0.4 ML?
HUMIRA(CF) PEN 40 MG/0.4 ML (NDC 00074055402) is labeled by AbbVie Inc., and CMS classifies it as a brand product.